Estimation of Cachexia among Cancer Patients Based on Four Definitions

Kathleen M Fox, John M Brooks, Shravanthi R Gandra, Richard Markus, Chiun-Fang Chiou, Kathleen M Fox, John M Brooks, Shravanthi R Gandra, Richard Markus, Chiun-Fang Chiou

Abstract

Objectives. Estimate and compare the proportion of cancer patients with cachexia using different definitions from available clinical data. Methods. Electronic medical records were examined to estimate the proportion of cancer patients with cachexia using 4 definitions: (1) ICD-9 diagnostic code of 799.4 (cachexia), (2) ICD-9 diagnosis of cachexia, anorexia, abnormal weight loss, or feeding difficulties, (3) prescription for megestrol acetate, oxandrolone, somatropin, or dronabinol, and (4) >/=5% weight loss. Patients with cancer of the stomach, pancreas, lung, colon/rectum, head/neck, esophagus, prostate, breast, or liver diagnosed between 1999 and 2004 were followed for cachexia. Results. Of 8541 cancer patients (60% men and 55% Caucasian), cachexia was observed in 2.4% of patients using the cachexia diagnostic code, 5.5% expanded diagnoses, 6.4% prescription medication definition, and 14.7% with >/=5% weight loss. Conclusions. The proportion of patients with cachexia varied considerably depending upon the definition employed, indicating that a standard operational definition is needed.

Figures

Figure 1
Figure 1
Pair-wise overlap between cachexia definitions and prescription medication definition.
Figure 2
Figure 2
Pair-wise overlap between cachexia definitions and weight loss definition.

References

    1. Tisdale MJ. Cachexia in cancer patients. Nature Reviews Cancer. 2002;2(11):862–871.
    1. Strasser F, Bruera ED. Update on anorexia and cachexia. Hematology/Oncology Clinics of North America. 2002;16(3):589–617.
    1. Argiles JM, Busquets S, Felipe A, Lopez-Soriano FJ. Muscle wasting in cancer and ageing: cachexia versus sarcopenia. Advances in Gerontology. 2006;18:39–54.
    1. Giordano KF, Jatoi A. The cancer anorexia/weight loss syndrome: therapeutic challenges. Current Oncology Reports. 2005;7(4):271–276.
    1. National Cancer Institute. Nutrition in cancer care, June 2009, .
    1. O'Gorman P, McMillan DC, McArdle CS. Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutrition and Cancer. 1999;35(2):127–129.
    1. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. American Journal of Medicine. 1980;69(4):491–497.
    1. Bruera E. ABC of palliative care: anorexia, cachexia, and nutrition. British Medical Journal. 1997;315(7117):1219–1222.
    1. O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutrition and Cancer. 1998;32(2):76–80.
    1. Persson C, Glimelius B. The relevance of weight loss for survival and quality of life in patients with advanced gastrointestinal cancer treated with palliative chemotherapy. Anticancer Research. 2002;22(6B):3661–3668.
    1. Scott HR, McMillan DC, Brown DJF, Forrest LM, McArdle CS, Milroy R. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer. 2003;40(3):295–299.
    1. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? European Journal of Cancer. 1998;34(4):503–509.
    1. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clinical Nutrition. 2008;27(6):793–799.
    1. Lainscak M, Filippatos GS, Gheorghiade M, Fonarow GC, Anker SD. Cachexia: common, deadly, with an urgent need for precise definition and new therapies. The American Journal of Cardiology. 2008;101(11) supplement 1:S8–S10.
    1. Springer J, von Haehling S, Anker SD. The need for a standardized definition for cachexia in chronic illness. Nature Clinical Practice Endocrinology and Metabolism. 2006;2(8):416–417.
    1. Palesty JA, Dudrick SJ. What we have learned about cachexia in gastrointestinal cancer. Digestive Diseases. 2003;21(3):198–213.
    1. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Annals of Oncology. 2001;12(3):289–300.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться